Abstract
Colchicine, a tricyclic alkaloid derived from Colchicum autumnale, is well known for its anti-inflammatory properties, and has been used to treat conditions such as gout, familial Mediterranean fever, and pericarditis. Colchicine's inhibition of the NLRP-3 inflammasome and reduction of key pro-inflammatory cytokines has been considered potentially beneficial in managing COVID-19. While early anecdotal reports and small-scale studies suggest potential benefits, including reduced hospital stay and oxygen requirements, larger randomized controlled trials (RCT) have largely failed to demonstrate significant improvement in mortality, the need for mechanical ventilation, or ICU admissions. Meta-analyses of RCT data corroborate these findings, showing no substantial benefit of colchicine in treating COVID-19. In non-hospitalized patients, the data also suggests limited efficacy, with some studies indicating potential benefit in specific subgroups, though these findings have not been consistently replicated. Colchicine for the treatment of cardiac injury in individuals infected with COVID-19 has also been an area of interest; despite early work suggesting benefit, subsequent RCTs have not shown clear benefit in this subgroup of patients. Overall, despite its promising mechanism of action, the evidence does not support the use of colchicine as standard treatment for COVID-19, either in hospitalized or community-based settings, or with evidence of cardiac injury. This review highlights the need for further research to better understand the potential role of colchicine – looking back as well as a look ahead – in the management of COVID-19.